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Abstract: Introduction: Modeling studies suggest intensified HIV testing, linkage-to-care and antiretroviral treatment to 
achieve viral suppression may reduce HIV transmission and lead to control of the epidemic. To study implementation of 
strategy, population-level data are needed to monitor outcomes of these interventions. US HIV surveillance systems are a 
potential source of these data. 
Methods: HPTN065 (TLC-Plus) Study is evaluating the feasibility of a test, linkage-to-care, and treat strategy for HIV 
prevention in two intervention communities - the Bronx, NY, and Washington, DC. Routinely collected laboratory data on 
diagnosed HIV cases in the national HIV surveillance system were used to select and randomize sites, and will be used to 
assess trial outcomes. 
Results: To inform study randomization, baseline data on site-aggregated study outcomes was provided from HIV 
surveillance data by New York City and Washington D.C. Departments of Health. The median site rate of linkage-to-care 
for newly diagnosed cases was 69% (IQR 50%-86%) in the Bronx and 54% (IQR 33%-71%) in Washington, D.C. In 
participating HIV care sites, the median site percent of patients with viral suppression (<400 copies/mL) was 57% (IQR 
53%-61%) in the Bronx and 64% (IQR 55%-72%) in Washington, D.C. 
Conclusions: In a novel use of site-aggregated surveillance data, baseline data was used to design and evaluate site 
randomized studies for both HIV test and HIV care sites. Surveillance data have the potential to inform and monitor site-
level health outcomes in HIV-infected patients. 
Keywords: HIV, linkage-to-care, site randomized, surveillance, test and treat, viral load suppression. 
INTRODUCTION 
 Evidence is accumulating that antiretroviral treatment of 
HIV-infected persons results in prevention of HIV 
transmission – that “treatment is prevention.” Observational 
and ecological evidence suggest that antiretroviral treatment 
(ART) reduces the risk of transmission to HIV-uninfected 
persons [1, 2]. Recent results from a randomized study 
(HPTN 052) established that ART initiation at CD4 counts 
between 350 and 550 cells/mm
3
 in the HIV infected partner 
reduced HIV transmission by 96% to the uninfected partner 
in discordant couples [3]. Given this demonstration of 
reduced HIV transmission through use of ART, the “test-
and-treat” strategy to decrease spread of HIV in the 
community is receiving serious operational consideration. 
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This strategy combines expanded HIV testing to identify 
undiagnosed HIV infection with prompt linkage-to-care and 
initiation of ART to lower HIV viral load (VL) levels [4-8]. 
People aware of their HIV infection have been shown in 
several studies to adopt safer behaviors [9], and HIV-
infected individuals adhering to effective treatment achieve 
VL suppression in the blood stream and genital tract and 
become less infectious, resulting in decreased HIV 
transmission [3, 10, 11]. In the United States, an estimated 
21% of people living with HIV do not know they are 
infected [12], less than 50% of Americans aged 18-64 report 
having been tested for HIV [13], and linkage-to-care and 
retention in care are suboptimal [14-18]. Nonetheless the 
test-and-treat strategy is compelling because it has the 
potential to lower infection risk for the entire population. 
Projects to assess the feasibility of achieving high coverage 
of testing, treatment, and viral suppression are critical for 
understanding how best to improve health outcomes among 
those with HIV infection and decrease their risk of 
transmission. 
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 Methods and designs for efficiently measuring the 
effectiveness of test and treat programs at the community 
level are urgently needed. Randomized clinical trials remain 
the gold standard for proving efficacy of new prevention 
interventions in a research setting with high fidelity of 
implementation and evaluation. As proven prevention 
interventions move from randomized clinical trials into 
implementation, the primary question changes from 
establishing efficacy in a clinical trial setting to evaluating 
effectiveness in program settings and, ultimately, in 
populations. 
 U.S. HIV surveillance systems are increasingly able to 
reliably monitor indicators of access to care for identified 
cases of persons living with HIV/AIDS, as laws mandating 
name based reporting of newly detected cases are 
implemented, along with mandatory reporting of HIV viral 
load and CD4 counts from laboratories within the 
jurisdiction to the surveillance systems [19, 20]. The 
surveillance systems thus have the potential to be used as a 
platform for evaluating interventions in persons known to be 
HIV-infected, building on current surveillance evaluations of 
linkage to care and retention in care [17, 21]. 
 The HPTN 065 (TLC-Plus) study was designed to 
determine the feasibility of implementing an "Enhanced 
Test, Link to Care, Plus Treat" approach for HIV prevention 
in the United States. The study incorporates two site-
randomized components to evaluate the effectiveness of 
financial incentives (FIs) for increasing linkage-to-care and 
VL suppression in two communities: the Bronx, NY and 
Washington, D.C. The study proposes a novel use of 
surveillance data to assess aggregate site outcomes in HIV 
infected patients accessing testing and care. Surveillance 
data was used to inform design and implementation of the 
site-randomized study components and will be used to assess 
the outcomes of the site level interventions. To our 
knowledge, HPTN 065 (TLC-Plus) is the first study to use 
HIV surveillance data to design and determine key HIV-
related health outcomes of interventions in a site-randomized 
trial. 
 In this paper we describe the use of baseline site 
aggregate data from surveillance systems in the Bronx, NY, 
and Washington, D.C. to design the financial incentive 
components of the study and conduct the randomization of 
the participating sites in the two study cities. Assessing 
baseline site aggregate measures provides a proof of concept 
for the future use of aggregate site data from surveillance 
systems for measuring the interventions’ effectiveness in 
HPTN065. 
METHODS 
HPTN 065 Study Design 
 HPTN 065 (TLC Plus) is a feasibility study of an 
enhanced, link to care, plus treat approach to HIV prevention 
that incorporates five components addressing different 
operational aspects of implementing a test and treat strategy 
for HIV prevention: expanded HIV testing, use of FIs for 
linkage to care, use of FIs for viral load suppression, a 
behavioral intervention for HIV-infected patients, and a 
survey of patient and provider attitudes to ART treatment for 
prevention. The study initiated in 2010 in the Bronx, NY, 
and Washington D.C., and is designed to gather data to 
inform the implementation of strategies for increasing HIV 
testing and improving access and adherence to HIV 
treatment for HIV infected patients. Increased HIV testing is 
being implemented in inpatient and emergency room settings 
in participating hospitals. Financial incentives are being 
evaluated for enhancing both linkage to care and viral 
suppression for HIV-infected persons: these components will 
be assessed in HIV testing and HIV care sites in the Bronx, 
NY and Washington DC, using New York City and 
Washington D.C. surveillance data. In addition, Department 
of Health (DOH) HIV testing and surveillance data from 
four non-intervention cities (Houston, TX; Miami, FL; 
Chicago, IL; Philadelphia, PA) will be used in an ecological 
comparison. This paper describes the use of surveillance data 
to implement the two financial incentive components of the 
study. 
HIV Surveillance System 
 Since 1982, all 50 U.S. states and the District of 
Columbia have reported AIDS cases to the Centers for 
Disease Control and Prevention (CDC) in a uniform format. 
In 1994, the CDC integrated national HIV case surveillance 
with AIDS case surveillance, at which time 25 states with 
confidential, name-based HIV surveillance started 
submitting HIV case reports to CDC. Over time, additional 
states adopted name-based HIV surveillance; all states had 
done so by April 2008. Cases are reported to the national 
HIV surveillance system at the CDC without identifying 
information. Assessments of potential duplicate case reports 
occur both at the state and national level; resolution of these 
duplicate reports occurs at the state level. 
 Data collected for HIV surveillance include demographic 
characteristics of persons diagnosed with HIV, as well as 
clinical, laboratory, and vital status information. Historically, 
information was collected only at the time of diagnosis of 
HIV, AIDS, and at the time of death. Over time, state and 
local laws and regulations required laboratories to report 
HIV-related diagnostic test information, including positive 
Western blot (WB) results, plasma VL test results and CD4 
counts to local DOH. With laboratory reporting of all HIV-
related test results, it is now possible to determine the stage 
of disease at diagnosis (through CD4 cell count), to assess 
utilization of HIV care sites based on laboratory tests 
performed at the sites (identified by the provider that ordered 
the test), and to monitor CD4 counts and VL levels in their 
population of patients over time. 
 Laboratory reporting can also provide information 
regarding the patients’ current address of residence and the 
location where they receive HIV care. Site information in the 
surveillance system allows aggregation of data by specific 
care site, which enables comparisons of the number of HIV- 
infected patients in care at individual sites, the CD4 counts 
and VL levels of their patient populations, and any changes 
related to interventions at specific sites. 
 Using surveillance systems to capture aggregate site 
outcomes requires high-quality surveillance data with 
complete capture of HIV-related laboratory results. The 
study is being conducted in Bronx, NY, and Washington, 
D.C., using surveillance data from the New York City and 
Washington D.C. DOH jurisdictions. New York City has had 
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mandatory electronic submission of positive WB and all VL 
and CD4 values from all testing laboratories to the DOH 
since 2005. Completeness and accuracy of dates, values and 
demographic data of CD4 counts and VLs are validated in 
the field by chart review, by monitoring of laboratory 
volume and domain values for each test type, as well as the 
patient identifiers that are used for matching, and by periodic 
laboratory audits that compare in-house laboratory data with 
data received by the New York State Electronic Clinical 
Laboratory Reporting System (ECLRS). The laboratory 
quality control duties are shared between New York City and 
New York State. All laboratories that currently perform 
HIV-related testing are enrolled in ECLRS, because all 
laboratories that perform any testing within New York State 
or for New York State providers are required to be certified 
for each test by the NYS Clinical Laboratory Evaluation 
Program (CLEP). Each time that CLEP approves a new 
laboratory or a new test for an enrolled laboratory, the NYS 
DOH contacts the laboratory, establishes or modifies any 
reporting system as required, and closely monitors startup 
through a thorough certification process that involves both 
test and production transmissions. Once the laboratory has 
been certified, it is routinely monitored as described above. 
 The Washington, D.C. DOH has rapidly achieved almost 
complete electronic reporting of HIV-related laboratory 
results following a major investment in surveillance data 
systems beginning in 2008. Paper-based laboratory data is 
manually entered. Completeness and accuracy of dates, 
values and demographic data of CD4s and VLs are validated 
in the field by chart review, and systems for routine 
monitoring of laboratory reporting are being defined. 
 Strict federal and state confidentiality constraints limit 
the disclosure of data from name-based HIV/AIDS 
surveillance systems. Only de-identified aggregate data can 
be released from the system. Analysis and publication of 
surveillance data broken down by demographic categories, 
risk factors, and diagnostic or care provider are routine. 
Because HPTN 065 requires only site-aggregated data, it is 
an appropriate extension of routine practice to use site 
aggregate data for planning and evaluation of the financial 
incentive components of HPTN 065. 
Financial Incentive Intervention 
 Two HIV-related interventions are being evaluated in 
two separate site-randomized components of HPTN 065: FI 
for increasing linkage-to-care for newly diagnosed cases and 
FI for increasing VL suppression for patients on ART. The 
duration of the interventions is two years at each site. 
Outcomes captured in surveillance data, aggregated within 
sites randomized to the two arms, will be used to assess the 
effectiveness of FIs. 
Site Selection 
 For the FI components of HPTN 065, the goal was to 
recruit 20 test and 20 care sites per municipality. For HIV 
test site selection, HIV test sites in the Bronx and 
Washington D.C. with the highest number of newly 
diagnosed HIV infections in the previous calendar year were 
identified using the most recent surveillance year available at 
the time of site recruitment and selection. For HIV care site 
selection, care sites in the Bronx and Washington, D.C. with 
the highest number of HIV infected patients were identified 
from the surveillance data. If more than 20 sites were 
recruited, sites with higher volume were selected. Selection 
and recruitment of sites relied on close coordination with the 
DOH in New York City and Washington, D.C. and extensive 
cooperation and communication with testing and health 
provider organizations. Many of the largest providers of HIV 
health care provide both HIV testing and care, and were 
eligible as both test and care sites. 
Study Outcomes 
 During study design, 2007 surveillance data from New 
York City and 2008 data from Washington D.C. were used 
to inform design parameters: i.e., to estimate size of site 
populations, study outcomes at baseline and intraclass 
correlation of outcomes across sites. At the time of study 
randomization, which occurred between October 2010 and 
March 2011, updated data - 2008 data from New York City 
and 2009 data from Washington D.C. - were used as baseline 
measures in conducting a restricted randomization of sites. 
Linkage-to-Care measures: The study outcome for asses-
sing linkage-to-care in HPTN 065 defines a case as linked to 
care when a VL or CD4 test result occurs within 3 months of 
an HIV-positive test at a participating test site. Site-
aggregated surveillance data for 1) the number of newly 
diagnosed HIV-infected cases identified at a site and 2) the 
proportion of these cases linked to care within three months 
was used as baseline data for conducting the randomization 
of selected test sites. 
Viral suppression measures: The study outcome for the VL 
suppression component of HPTN 065 defines a case with 
suppressed VL when VL is < 400 copies/mL among HIV-
infected patients in care (previous VL or CD4 count) at a 
participating site. The surveillance systems do not capture 
information about ART, thus the study outcome is assessed 
in all HIV-infected patients in care, irrespective of ART. The 
site-aggregated surveillance data for: 1) the number of HIV-
infected patients with a care visit at the site in the 
corresponding calendar year, and 2) the proportion of those 
patients with VL suppression at the last visit were used as 
baseline data for randomization of the selected care sites. 
Randomization Procedures 
 The goal of the restricted randomization procedure was 
to ensure balance between arms of two site characteristics 
that were likely highly predictive of study outcomes: 1) 
baseline case volume and 2) study outcomes at baseline [22]. 
Sites were randomized after they had obtained IRB 
approvals, and randomizations were conducted in blocks as 
IRB approvals were obtained. Each city and each component 
was randomized independently. To select a site 
randomization for a component and group of sites, all 
possible 1: 1 randomizations were computed and ranked for 
balance in the respective baseline number of cases and 
outcome (baseline linkage-to-care and viral load suppression, 
respectively) in each arm. Balance was computed using the 
following index for a given randomization into two groups 
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where the site patient volumes, V, and outcome proportions, 
P, are divided into the two groups and V(R1,R2) and P(R1,R2) 
are the unequal variance t-statistics comparing mean volume 
and mean outcome proportion, respectively, between the two 
groups i.e.: 











 When randomizations were conducted in blocks, later 
blocks calculated the index including the previously 
randomized sites to ensure overall balance was maintained. 
In each block, the chosen randomization was selected at 
random from the N randomizations with highest rank (N 
varied with the number of sites being randomized). Where 
the number of sites was unequal, the number of sites in each 
arm could only differ by 1. 
 Randomization for the linkage-to-care and the viral 
suppression components could be conducted independently, 
even though some sites operated as both test and care sites, 
as the two interventions occur at different times for an HIV 
infected patient: the linkage-to-care intervention is triggered 
by an HIV-positive test (likely before a person is in care), 
whereas the intervention for VL suppression is initiated 
amongst patients on antiretroviral therapy. 
RESULTS 
Site Selection and Randomization 
 In the Bronx, 27 HIV test sites were identified and 
approached, of which 18 were ultimately recruited for 
participation in the study. In Washington D.C., 31 test sites 
were identified and 28 sites approached, of which 19 were 
recruited for the study (Fig. 1). Only 6 sites in the Bronx and 
3 in Washington D.C. did not respond or declined 
participation. Test site randomization occurred from Bronx 
sites in February, 2011, using data from 2008 and for 
Washington D.C. in February and March 2011, using data 
from 2009. 
 Thirty-six care sites were approached in the Bronx, and 
20 highest volume sites were selected for participation in the 
study. In Washington, D.C., 32 care sites were identified and 
27 approached, of which 19 were recruited. Seven sites in 
the Bronx and 4 in Washington, D.C. did not respond or 
declined participation (Fig. 2). Care site randomization 
occurred in the Bronx in January 2011, and for Washington, 
D.C., in October 2010 and January 2011. 
 For either intervention, a site could only be randomized if 
they were able to implement the FI intervention within the 
patients attending that clinic and site data could be clearly 
identified within the surveillance system. Three test sites 
originally planned to be randomized as separate sites 
ultimately had to be combined because individual site data 
could not be reliably identified in surveillance. Five care 
sites also were combined either because of operational 
dependence (e.g. patients frequently scheduled at different 
clinics in the same provider system) or because centralized 
lab processing in the provider system meant data could not 
be clearly identified in surveillance systems. 12 of the 
selected sites in the Bronx and 11 in Washington D.C. are 
both test and care sites. 
Baseline Site Aggregate Data for Linkage-to-Care 
 Surveillance data on the number of new diagnoses and 
linkage-to-care proportions used for selecting a 
randomization of the participating test sites is given in Table 
1. Four sites in the Bronx and Washington, D.C. identified 
more than 50 newly diagnosed HIV cases in 2008 and 2009, 
respectively. An additional 5 sites in the Bronx and 9 sites in 
Washington D.C. identified between 10 and 50 newly 
identified cases, and the remaining 15 each found fewer than 
 
Fig. (1). Selection of test sites. 
 
Sites Combined: 2
Low volume of patients: 3 
Declined: 1
Did not respond: 3
Total number of care sites identified by 
DOH: 36
Number of sites approached: 36
Number of sites that signed LoI: 25






Total number of care sites identified by 
DOH: 32
Number of sites that signed LoI: 23






Number of sites approached: 27
No longer seeing HIV-infected: 2
Declined 3




Bronx NY Washington D.C.
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10 cases. The median proportion of newly identified HIV 
cases linked to care within three months of initial diagnosis 
in 2008 in the Bronx sites was 69%, (interquartile 
range(IQR) 50%-86%); in Washington, D.C., for cases 
diagnosed in 2009, the median proportion linked to care was 
54% (IQR 33%-71%). 
VL Suppression Component 
 Table 2 shows the number of HIV-infected patients with 
care visits (i.e., CD4 or VL measures in the calendar year) 
and proportion of patients whose last VL was suppressed 
based on 2008 surveillance data for the Bronx and 2009 
surveillance data for Washington, D.C. Five sites in the 
Bronx and two in Washington, D.C. had in excess of 1000 
HIV-infected patients with care visits, 14 and 9 sites 
respectively had between 100 and 1000 patients, and the 
remaining sites had fewer than 100 patients. The proportion 
of patients with VL suppression at their most recent visit was 
similar across care sites, with median rates of VL 
suppression in site populations of 57% (IQR 53%-61%) in 
the Bronx and 64% (IQR 55%-72%) in Washington, D.C. 
 The 20 participating HIV care sites in the Bronx 
registered approximately 12,500 HIV-infected patients in the 
2008 surveillance data; the 19 participating sites in 
Washington, D.C. registered approximately 5,900 HIV-
infected cases in the 2009 surveillance data. In the Bronx, 
the median number of patients per clinic with a care visit in 
2008 at the 20 participating sites was 251, ranging from 83 
to 2,751. In Washington DC, the median number of patients 
per clinic with a care visit was 153, ranging from 8 to 1,425 
in the 19 clinics. 
Study Power 
 Study power calculations were based on surveillance data 
from 2007 for the Bronx and 2008 for Washington, DC (data 
not shown). Sample size calculation for the site randomized 
designs used the approach described by Thomson, Hayes and 
Cousens [23, 24]. Assuming 20 sites per arm, a mean 
number of HIV-positive cases of 100 per testing site over the 
two year period, and an intraclass correlation of 0.31, the 
study would have 80% power to detect an increase from 67% 
to 80% linked to care within 3 months. The intraclass 
correlation for baseline linkage to care within testing sites in 
the Bronx was 0.27, within Washington D.C. was 0.31. For 
care sites, assuming 20 sites per arm, a mean number of 
cases in care of 180 patients, and an intraclass correlation of 
0.11, the study would have 80% power to detect an increase 
in patients with viral suppression from 60% to 66% between 
the standard of care and FI clinics. The intraclass correlation 
for baseline viral suppression within care sites in the Bronx 
was 0.07, within Washington D.C. was 0.10. 
DISCUSSION 
 The National HIV surveillance system has provided 
invaluable information for the monitoring of the US 
epidemic since its inception, including insights on the 
changing demographics and transmission categories, changes 
in prevalence and mortality, and estimation of HIV incidence 
[12, 23, 24]. A study in the San Francisco DOH found that 
monitoring of VL and CD4 count evaluations from 
laboratory reporting increased detection of initial primary 
care visits by 25% above standard HIV public health 
investigation [19], indicating that complete reporting of 
laboratory data to the DOH offers increasingly complete 
capture for monitoring care visits in known HIV cases. HIV 
surveillance data have also been used to assess the size of the 
diagnosed HIV-infected populations currently living in 
defined jurisdictions, and to map ecologic trends in newly 
diagnosed infections and transmission potential in a 
community based on the measured and imputed aggregate 
mean VL of the HIV-infected population [25, 26]. In 
addition, increasing confidence in the surveillance data has  
led the CDC to support local health departments to initiate 
programs to increase HIV testing and strengthen linkage-to-
care and treatment. 
 
Fig. (2). Selection of care sites. 
Sites combined:  1 
Did not respond: 3
Total number of test sites identified 
by DoH: 27
Number of sites approached: 27
Number of sites that signed LoI: 19





to SOC:  9
Total number of test sites identified by 
DOH: 31
Number of sites that signed LoI: 25






Number of sites approached: 28
No longer seeing HIV-infected: 2
Declined: 3
Did not respond: 3
Combined: 2
Test volume too low : 4
Bronx NY Washington D.C.
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 Conducting site-randomized trials is a complex 
undertaking, requiring careful discernment to define the 
cohort to be assessed and to establish data systems for 
measuring site-level outcomes [27]. Surveillance data 
systems can provide comprehensive and accurate estimates 
of site-level measures and key epidemic indicators for cases 
that make such trials more operationally feasible and 
potentially less expensive, especially if utilizing the 
complete capture of laboratory-based state and local public 
health surveillance systems. 
 Surveillance data can only be used to evaluate public 
health interventions in which study outcomes are aggregated 
across patients because no individual patient data that 
originate in surveillance can be used for patient-level 
research. Measurement of an intervention effect requires 
outcomes that are reliably captured within the surveillance 
population (e.g., laboratory measures and events at diagnosis 
in known cases of HIV infection) and can be aggregated 
across the chosen site-randomized patient population. Thus, 
for example, surveillance data cannot measure the impact of 
an intervention to increase HIV testing at a site, because the 
number of HIV tests at a site and the HIV-negative results 
are not captured in the HIV case surveillance system. 
 A significant advantage of using existing, ongoing data 
systems is standardized, reproducible baseline data that can 
be used to inform design parameters of a site-randomized 
trial. This can significantly increase the power of the study to 
detect an effect [28]. Baseline levels of study outcomes can 
be used to conduct a randomization with a higher probability 
of balance, protecting both power and Type I error. 
Estimates of the intraclass correlation, a parameter rarely 
available at the design stage of a site-randomized trial, also 
help ensure accurate power assessment in the trial. In the 
HPTN 065 viral suppression component, for example, the 
relative consistency of baseline proportions of VL 
suppression suggest that the study is likely to have adequate 
power to detect an 6% increase in VL suppression. In 
comparison, the variability among test sites in both numbers 
of new cases and linkage-to-care proportions presents a 
scenario where the study could only reliably detect an 
increase greater than 13%. However, it must be cautioned 
that the 1-2 year lag between the baseline surveillance data 
and trial implementation make the randomization vulnerable 
Table 1. Number of Cases and Linkage to Care at Baseline for Participating HIV Testing Sites in Bronx, N.Y. and Washington, 
D.C. 
 
The Bronx (2008) Washington, D.C. (2009) 
Site Number of Newly  
Identified HIV-Infected  
Individuals in 1 Year* 
Baseline Rates of Linkage-to-Care: 
Initiating Care within 3 Month of 
HIV Diagnosis, Data for 1 Year 
Number of Newly  
Identified HIV-Infected  
Individuals in 1 Year* 
Baseline Rates of Linkage-to-Care: 
Initiating Care within 3 Months of 
HIV Diagnosis, Data for 1 Year 
1 110 89% 186 51% 
2 103 89% 117 45% 
3 54 85% 98 61% 
4 51 82% 88 32% 
5 47 81% 45 42% 
6 35 91% 43 58% 
7 32 72% 24 0% 
8 30 67% 21 33% 
9 18 67% 21 0% 
10 7 100% 20 70% 
11 4 50% 19 74% 
12 4 50% 18 83% 
13 4 0% 14 57% 
14 2 50% 3 100% 
15 2 50% 3 0% 
16 2 50% 1 100% 
17 0 n/a  0 n/a  
18 0 n/a 0 n/a  







*Sites were initially selected using 2007 data from New York City and 2008 data from Washington D.C. At the time of randomization more recent data was available in New York 
City (2008) and Washington D.C. (2009), and used in selecting a randomization. Several sites had new cases reported in the selection data but no newly diagnosed infections reported 
in the more recent randomization data. 
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to unmeasured and/or as-yet-unknown administrative and 
mission changes in HIV test and care sites. 
 The standardization of surveillance systems across the 
US permits “ecologic” comparisons of trends in non-
intervention cities compared to observed trends in the 
intervention communities in HPTN 065. With a national 
surveillance system, the expense of implementing study-
specific data collection in other cities is avoided, although 
resources are needed for additional programming to 
implement the study-specific definitions of cohorts, 
outcomes, and evaluation periods at the non-intervention 
DOH. 
 While using surveillance systems has many advantages, 
to achieve high completeness in study outcome measures 
may require a significant reporting delay. All data systems 
experience reporting lag, but the passive nature of 
surveillance leads to a longer lag than in dedicated trial data 
collection systems, potentially resulting in a significant delay 
before the reporting of interim and final trial results. It is 
typical for annual surveillance data reporting new diagnoses 
of HIV to be finalized after one year, as reflected in the use 
of 2008 and 2009 data for study implementation in 2010 and 
2011. The most significant lag currently occurs with 
verification of new diagnoses: the laboratory report that 
identifies an individual as a possible new diagnosis of HIV 
must be de-duplicated and matched to the national 
surveillance registry and, if not matched, a field investigation 
completed to confirm the date and disposition of diagnosis 
and collect all other data required for surveillance. Both 
CDC and the state and local surveillance authorities have 
determined that a nine-month period between the date of 
initial HIV diagnosis (the draw date of the blood for the test 
that confirmed the HIV diagnosis) to confirmation of 
diagnosis and entry into the registry is required before 
reporting is >90% complete. However, reporting of 
laboratory data to update an existing registry record of 
patient, used for the viral suppression component of HPTN 
065, is considerably more rapid. For example, reporting is 
complete within three months of draw date for laboratory 
results (CD4 and/or VL) from known HIV patients in 
jurisdictions with electronic laboratory reporting. Case 
migration is also a challenge: there is inevitably a lag in 
resolving data, particularly date of initial diagnosis, from 
Table 2. Number of Cases and HIV Plasma Viral Load Suppression (<400 Copies/mL) at Baseline for Participating HIV Care 
Sites in Bronx, N.Y. and Washington, D.C. 
 
The Bronx, NY(2008) Washington, D.C. (2009) 
Site 
Number of HIV-Infected 
Patients in Care 




Number of HIV-Infected 
Patients in Care 
Proportion of HIV-Infected 
Patients with VL Suppressed
1
 
1 2,751 59% 1,425 72% 
2 2,500* 69% 1,138 58% 
3 1,483 60% 675 59% 
4 1,176 57% 482 87% 
5 1,118 56% 376 61% 
6 702 50% 321 66% 
7 379 58% 319 73% 
8 376 56% 296 89% 
9 277 56% 289 64% 
10 275 63% 153 53% 
11 227 66% 107 77% 
12 210 39% 98 30% 
13 180 66% 67 64% 
14 173 55% 60 63% 
15 131 63% 41 73% 
16 130* 45% 33 36% 
17 119 36% 15 67% 
18 118 39% 12 50% 
19 103 58% 8 0% 







*Site reported patient volume. 
1VL suppression (< 400 copies/mL) achieved at last visit in calendar year specified. 
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cases relocated from elsewhere, or cases accessing care in 
the study jurisdiction but residing in a different jurisdiction. 
De-duplication across jurisdictions of data captured in the 
state and local surveillance systems occurs through the 
national CDC database. 
 A known challenge in assessing aggregate site outcomes 
is the requirement for specificity and completeness of site 
location fields on the laboratory requisition that allows 
surveillance to track laboratory results back to the ordering 
site. This relies on the procedures of participating sites, and 
coordination between providers and the DOH. While our 
success in obtaining and utilizing site-specific data for 
baseline measures establishes proof of concept for measuring 
site-level outcomes through the HIV surveillance systems, 
the data were known to imperfectly identify site for a 
substantial fraction of laboratory reports; for example, self-
reported baseline data were used in the design stage for two 
care sites that are part of a large multi-site care system 
because of known problems with identifying the specific site 
from which the laboratory specimen emanated in the 
surveillance data. Improvements in the consistency of site 
identifying fields will be required to ensure accurate 
attribution of data to specific site locations for HPTN 065 
study outcomes, as lack of precision will threaten the ability 
to detect change resulting from the interventions. Additional 
staffing resources for acquiring site attribution for study 
outcomes are being provided to the Departments of Health of 
participating jurisdictions. 
 Use of the surveillance data to assess aggregate site 
outcomes would not be possible in jurisdictions without 
reporting of all laboratory values, with poor quality 
monitoring of laboratory data, or with large data entry 
backlogs. All states have mandatory name-based laboratory 
reporting of positive HIV test results, but only 28 states, 
Washington, D.C. and Puerto Rico, currently have 
mandatory reporting of all CD4 and VL values; some states 
only require CD4<200 or detectable VL to be reported. 
Some jurisdictions, including New York City, also have 
mandated electronic reporting to the DOH, which is clearly 
an advantage for achieving complete and timely reporting. 
Many jurisdictions are improving their systems to utilize 
electronic reporting from laboratories to ease the upload of 
data into the surveillance system. HPTN 065 is evaluating 
the use of surveillance data in an additional four 
communities that serve as non-intervention communities in 
this study (Houston, TX Miami, FL; Chicago, IL; 
Philadelphia, PA). By evaluating the issues encountered 
across a broad range of cities affected by the HIV epidemic, 
we plan to assess the human and technical resources required 
to use surveillance data for evaluating public health 
strategies in site-randomized studies. 
 HPTN 065 benefits from extensive CDC investment in 
the DOHs HIV surveillance systems of each of these six 
communities: Each jurisdiction has created and executed 
HIV testing campaigns in the community, taking advantage 
of additional funding opportunities available through the 
CDC following the publication of the revised CDC testing 
recommendations in 2006 [29]. A collateral benefit of these 
CDC- funded activities is good working relationships 
between DOH and HIV care and testing providers, and 
detailed prior knowledge of HIV test and care facilities 
throughout the community. This is reflected in the high 
participation rates amongst selected sites in both intervention 
cities in our study. 
CONCLUSION 
 Name-based HIV surveillance systems with 
comprehensive laboratory reporting of HIV-related tests 
have led to the ability to assess strategies using site level 
outcomes, offering a new opportunity to conduct program 
evaluations outside of the specialized research sites that are 
typically required to measure intervention effects. A site-
randomized trial can be designed and implemented that uses 
a systematic and comprehensive assessment of site-level 
impact, and assessment can be achieved using data from 
surveillance systems without incurring the full complexity of 
establishing an independent data collection system for the 
study. 
 HPTN 065 (TLC-Plus) is taking a novel approach to 
evaluating implementation programs using a site-randomized 
design and relying on existing surveillance data for assessing 
outcomes. This approach has great potential for future 
evaluation of implementation strategies in the U.S. and other 
countries with similar surveillance systems. 
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